Cardiometabolic Health in Women: Risks, Conditions, and Evidence-Based Treatment

Why Cardiometabolic Risk Is Different in Women

Women face a distinct cardiometabolic risk profile shaped by reproductive hormones, pregnancy-specific conditions, and immune biology that diverges sharply from the male template used in most foundational research. The American Heart Association's 2021 guidance on cardiovascular disease in women explicitly states that "sex-specific risk factors such as hypertensive disorders of pregnancy, premature menopause, and autoimmune conditions are underweighted in standard risk calculators." [1]

Cardiovascular disease accounts for approximately 299,000 female deaths annually in the United States, according to the CDC. [2] Despite that burden, the WISE (Women's Ischemia Syndrome Evaluation) study found that women presenting with chest pain are significantly more likely than men to have non-obstructive coronary artery disease, a pattern linked to microvascular dysfunction rather than plaque rupture. [3] That biological difference leads to misdiagnosis and delayed intervention.

Estrogen exerts direct atheroprotective effects through nitric oxide upregulation and anti-inflammatory cytokine modulation. The sharp estrogen withdrawal at menopause drives visceral fat redistribution, worsens insulin sensitivity, and raises LDL by roughly 10 to 15 mg/dL within 24 months. [4] Recognizing these inflection points, the 2023 ACC/AHA Guideline on Cardiovascular Risk Reduction in Women calls for re-screening lipids and fasting glucose within one year of the final menstrual period. [5]

Sex-specific risk multipliers also include preeclampsia (which doubles lifetime cardiovascular risk), autoimmune diseases such as systemic lupus erythematosus (which raises MI risk 2, 3 fold in women under 55), and depression, which carries a stronger association with incident coronary artery disease in women than in men. [6]

Diabetes in Women: Presentation, Progression, and Sex-Specific Gaps

Type 2 diabetes carries a 40% greater excess relative risk for fatal coronary heart disease in women compared with men, according to a 2014 meta-analysis in Diabetologia covering 858,507 individuals. [7] Women with diabetes also lose the normal female survival advantage for stroke, reaching stroke rates equivalent to men with diabetes. [8]

Symptoms often present atypically. Recurrent vulvovaginal candidiasis is frequently the first clinical clue of uncontrolled hyperglycemia in women. Fatigue, weight gain, and mood changes are often attributed to thyroid disease or perimenopause rather than prompting a glucose workup.

Polycystic ovary syndrome (PCOS) affects 6 to 12% of reproductive-age women and is the most common endocrine disorder in this group. [9] Insulin resistance is present in approximately 70 to 80% of women with PCOS regardless of body weight, and the lifetime risk of type 2 diabetes is 2, 4 times higher than in matched controls. [10] The Endocrine Society's 2023 Clinical Practice Guideline on PCOS recommends fasting glucose and oral glucose tolerance testing every 3 to 5 years in all women with PCOS, or annually when additional risk factors are present. [11]

GLP-1 receptor agonists have redefined outcomes in this population. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001), with a majority-female cohort. [12] In women with PCOS specifically, liraglutide 1.8 mg over 12 weeks significantly reduced free androgen index and improved menstrual regularity in the SARA (Semaglutide And Reproductive Androgens) pilot study. [13]

Metformin remains first-line for type 2 diabetes in women without contraindications. For women with established cardiovascular disease or high risk, empagliflozin and semaglutide carry Class I guideline recommendations from the 2023 ADA Standards of Care. [14]

Gestational Diabetes: Screening, Management, and Long-Term Risk

Gestational diabetes mellitus (GDM) affects 6 to 9% of US pregnancies and is rising with increasing maternal age and obesity rates. [15] The condition carries consequences that extend well past delivery. Women with a history of GDM face a 7-fold higher lifetime risk of developing type 2 diabetes, according to a systematic review published in JAMA Internal Medicine. [16]

The American Diabetes Association recommends universal 24 to 28 week screening with a 75-g oral glucose tolerance test (OGTT) using Carpenter-Coustan criteria: fasting glucose ≥92 mg/dL, 1-hour ≥180 mg/dL, or 2-hour ≥153 mg/dL. [17] Women with risk factors including BMI >30, prior GDM, or first-degree family history of diabetes should receive early screening at the first prenatal visit. [18]

Dietary management anchors GDM treatment. Carbohydrate intake should be distributed across three moderate meals and two to three snacks daily, targeting 175 g total carbohydrate minimum to prevent ketosis while staying below glycemic thresholds. The Academy of Nutrition and Dietetics specifically advises against very-low-carbohydrate diets (<130 g/day) in pregnancy. [19]

Insulin is the preferred pharmacologic agent for GDM requiring medication because it does not cross the placenta in clinically significant amounts. NPH and rapid-acting analogs (aspart, lispro) are both FDA-approved for use in pregnancy. [20] Metformin is sometimes used as second-line therapy; however, it does cross the placenta, and the MFMU Metformin in GDM trial showed non-inferior glycemic control but higher rates of neonatal hypoglycemia versus insulin in specific sub-groups. [21]

GLP-1 receptor agonists including semaglutide, liraglutide, and tirzepatide are contraindicated in pregnancy. Animal studies show fetal growth restriction and skeletal malformations at clinically relevant exposures, and the FDA label for Ozempic (semaglutide) carries a Pregnancy Category warning advising discontinuation at least two months before a planned conception. [22]

Postpartum follow-up is poor. Fewer than 50% of women with prior GDM receive postpartum glucose testing within the recommended 4, 12-week window. [23] The CDC's National Diabetes Prevention Program accepts women with prior GDM as eligible for the structured lifestyle intervention, which cuts progression to type 2 diabetes by 58% over three years. [24]

Cardiometabolic Health in Older Women

After menopause, women's cardiovascular risk accelerates rapidly. The Framingham Heart Study data show that the 10-year coronary heart disease risk in women roughly doubles in the decade following the final menstrual period, driven by concurrent changes in lipids, blood pressure, and body composition. [25]

Visceral adiposity increases by approximately 2 to 3 kg over the menopausal transition even without total weight gain, worsening insulin resistance and raising fasting triglycerides. [26] LDL particles also shift toward a denser, more atherogenic subtype post-menopause, a change not fully captured by standard LDL-C measurements. [27]

Statin therapy for primary prevention in older women remains an area of active clinical debate. The USPSTF 2022 updated recommendation supports statin use for adults aged 40, 75 with a 10-year CVD risk of 10% or more and at least one cardiovascular risk factor. [28] Women are systematically undertreated: a 2019 JAMA Cardiology analysis found women are approximately 20% less likely than men to be prescribed guideline-indicated statin therapy after a first myocardial infarction. [29]

Hormone therapy and cardiometabolic risk require careful framing. The Women's Health Initiative (WHI) trial raised concern over combined conjugated equine estrogen plus medroxyprogesterone acetate, reporting a hazard ratio of 1.24 for coronary heart disease events in the combined-arm cohort. [30] Subsequent re-analysis stratified by age at initiation showed the "timing hypothesis": women who began therapy within 10 years of menopause had a non-significant trend toward lower coronary event rates, while those starting more than 20 years post-menopause showed harm. [31] The Menopause Society (formerly NAMS) 2022 position statement states that hormone therapy is appropriate for healthy women under 60 or within 10 years of menopause who have bothersome vasomotor symptoms and no contraindications, and that cardiovascular risk should be individualized rather than assumed. [32]

SGLT2 inhibitors offer particular benefit in older women with established heart failure or chronic kidney disease. In EMPA-REG OUTCOME (N=7,020), empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalized heart failure by 25% (HR 0.75; 95% CI 0.65, 0.86). [33] The DAPA-HF trial showed comparable benefit with dapagliflozin, with consistent effect sizes in women across both preserved and reduced ejection fraction subgroups. [34]

Blood pressure targets matter differently by sex. Women develop hypertension-related cardiac damage at lower blood pressures than men, a finding confirmed in the SPRINT trial sub-group analysis showing that women achieved greater absolute reduction in composite cardiovascular events per mmHg systolic reduction than men did. [35]

Cardiometabolic Health in Female Athletes

Physical training protects cardiometabolic function, but the picture is more complex in competitive female athletes facing caloric restriction. The female athlete triad, now classified within the broader Relative Energy Deficiency in Sport (RED-S) framework, describes the cluster of low energy availability, menstrual dysfunction, and impaired bone mineral density that can appear even in athletes who appear lean and healthy. [36]

Low energy availability below approximately 30 kcal/kg of fat-free mass per day suppresses the hypothalamic-pituitary-gonadal axis, reducing LH pulsatility within 5 days of energy restriction in controlled studies. [37] The downstream consequence is functional hypothalamic amenorrhea, which causes prolonged hypoestrogenism. Even short durations of hypoestrogenism increase endothelial dysfunction scores and worsen flow-mediated dilation, markers of early atherosclerotic risk. [38]

Fasting insulin resistance rises in hypoestrogenic amenorrheic athletes compared with eumenorrheic athletes of identical training volume, according to a study published in the Journal of Clinical Endocrinology and Metabolism. [39] That finding challenges the assumption that exercise is uniformly cardioprotective regardless of hormonal status.

The RED-S Clinical Assessment Tool (CAT), endorsed by the International Olympic Committee's 2023 consensus statement, grades return-to-sport risk across 10 physiological domains including metabolic rate, lipid profile, and insulin sensitivity. Clinicians evaluating female athletes with menstrual irregularity should obtain fasting glucose, fasting lipids, and a resting metabolic rate assessment alongside the standard bone density scan. [40]

Therapeutic refeeding, not pharmacologic intervention, is first-line. Restoring energy availability to above 45 kcal/kg fat-free mass per day normalizes LH pulsatility in most women within 2 to 3 months. Combined oral contraceptives do not adequately substitute for restoration of endogenous estrogen in this context and have been shown to suppress IGF-1, potentially worsening bone outcomes. [41]

Elite endurance athletes who maintain adequate energy availability actually show favorable cardiometabolic profiles. A cross-sectional analysis in the British Journal of Sports Medicine found that eumenorrheic female endurance athletes had significantly lower carotid intima-media thickness and higher HDL-C than sedentary matched controls. [42] The distinction lies entirely in energy balance and hormonal status, not exercise volume.

Metabolic Syndrome and Cardiovascular Risk Scoring in Women

Metabolic syndrome affects approximately 35% of US adults, with rates rising sharply after age 50 in women due to menopausal hormonal changes. [43] The harmonized IDF/AHA/NHLBI definition requires three of five criteria: waist circumference >88 cm in women, triglycerides ≥150 mg/dL, HDL <50 mg/dL in women, blood pressure ≥130/85 mmHg, or fasting glucose ≥100 mg/dL. [44]

Standard cardiovascular risk calculators underestimate risk in women. The Pooled Cohort Equations have been shown to overestimate risk in some populations but underestimate it in younger women with autoimmune disease, prior adverse pregnancy outcomes, or premature ovarian insufficiency. [45] The 2019 ACC/AHA Primary Prevention Guideline explicitly lists these "risk-enhancing factors" as indications for downward age adjustment in risk scoring. [5]

Waist circumference is a particularly strong predictor in women. Each 5 cm increase above 88 cm confers approximately a 10% increase in metabolic syndrome prevalence in NHANES cross-sectional data, and the association holds after controlling for BMI. [46] Clinicians should measure waist circumference at every cardiometabolic visit for women, not just track weight.

Tirzepatide (Mounjaro, Zepbound) targets both GIP and GLP-1 receptors and produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539), the largest weight-loss trial of any GLP-1 class agent to date. [47] Waist circumference reduction averaged 14.6 cm in the highest dose group, translating directly to metabolic syndrome reversal in a substantial proportion of participants.

Treatment Priorities: A Sex-Conscious Clinical Approach

Effective treatment of cardiometabolic disease in women requires addressing the conditions that are either exclusive to women or substantially different in women compared with men. Gestational diabetes demands aggressive postpartum follow-up. PCOS warrants metabolic screening independent of BMI. Perimenopause is an opportunity for primary cardiovascular prevention, not merely symptom management.

Lifestyle modification produces consistent and measurable benefit. The Diabetes Prevention Program (DPP, N=3,234) showed that intensive lifestyle intervention reduced progression from prediabetes to type 2 diabetes by 58% at three years, outperforming metformin (31% reduction) in women. [24] Women in the lifestyle arm who lost at least 7% of body weight drove the majority of the benefit.

For pharmacologic therapy, guideline-directed selection should account for sex-specific side effect profiles. Statins carry a modestly higher rate of myopathy in women, possibly related to lower lean body mass and higher statin exposure per kilogram. [48] ACE inhibitors are teratogenic and must be stopped before conception or immediately upon confirmed pregnancy. GLP-1 receptor agonists should be discontinued at least two months before planned pregnancy given animal reproductive toxicity data. [22]

Blood pressure management to <130/80 mmHg is recommended for most women with hypertension by the 2017 ACC/AHA Hypertension Guideline, with thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers all carrying Class I indications. [49] Women with chronic kidney disease or proteinuria should receive ACE inhibitor or ARB as preferred first-line agents. [50]

The ADA's 2024 Standards of Care in Diabetes reaffirms that for women with type 2 diabetes and established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit (semaglutide, liraglutide, or dulaglutide) should be added to metformin regardless of baseline HbA1c. [14] Semaglutide 0.5 to 1 mg weekly in SUSTAIN-6 (N=3,297) reduced major adverse cardiovascular events by 26% versus placebo (HR 0.74; 95% CI 0.58, 0.95). [51]

Women who are candidates for tirzepatide should know that SURMOUNT-CVD data, published in 2024, showed a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease over a median follow-up of 3.4 years, with the benefit consistent across sex subgroups. [52]

Assess each woman's reproductive plans before initiating any cardiometabolic pharmacotherapy. A 30-year-old woman with PCOS, prediabetes, and a BMI of 34 kg/m2 planning pregnancy within 12 months needs a different regimen than a 60-year-old woman with the same metabolic profile and no reproductive considerations.